<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 14 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:inherit;
panose-1:0 0 0 0 0 0 0 0 0 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
h3
{mso-style-priority:9;
mso-style-link:"Heading 3 Char";
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:13.5pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Times New Roman","serif";
font-weight:bold;}
span.Heading3Char
{mso-style-name:"Heading 3 Char";
mso-style-priority:9;
mso-style-link:"Heading 3";
font-family:"Times New Roman","serif";
font-weight:bold;}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:windowtext;}
span.by-author
{mso-style-name:by-author;}
span.apple-converted-space
{mso-style-name:apple-converted-space;}
span.author
{mso-style-name:author;}
span.posted-on
{mso-style-name:posted-on;}
span.sharing-screen-reader-text
{mso-style-name:sharing-screen-reader-text;}
span.share-count
{mso-style-name:share-count;}
span.EmailStyle27
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-US link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0in 0in 0in'><p class=MsoNormal><b><span style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>>…</span></b><span style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> <b>On Behalf Of </b>spike<br><b>Subject:</b> [ExI] wooohooo! this is our hell mary bill<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><a href="http://stateofreform.com/news/industry/healthcare-providers/2015/06/ca-senate-committee-to-hear-right-to-try-bill/?cal">http://stateofreform.com/news/industry/healthcare-providers/2015/06/ca-senate-committee-to-hear-right-to-try-bill/?cal</a><o:p></o:p></p><h1 style='vertical-align:baseline'><span style='font-family:"inherit","serif";color:#222222'>CA: Senate committee to hear “Right to Try” bill<o:p></o:p></span></h1><p class=MsoNormal><span class=by-author><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'>By</span></span><span class=apple-converted-space><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'> </span></span><span class=author><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'><a href="http://stateofreform.com/author/jon/" title="View all posts by Jon Brumbach"><span style='color:#999999'>Jon Brumbach</span></a></span></span><span class=apple-converted-space><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'> </span></span><span class=posted-on><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'>,</span></span><span class=apple-converted-space><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'> </span></span><span class=author><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'><a href="http://stateofreform.com/news/industry/healthcare-providers/2015/06/ca-senate-committee-to-hear-right-to-try-bill/" title="8:00 am"><span style='color:#999999'>June 12, 2015</span></a></span></span><span style='font-family:"Times New Roman","serif"'><o:p></o:p></span></p><p style='margin:0in;margin-bottom:.0001pt;background:white;vertical-align:baseline'><span style='font-size:9.5pt;font-family:"Helvetica","sans-serif";color:#373940'><o:p> </o:p></span></p><p style='margin:0in;margin-bottom:.0001pt;background:white;vertical-align:baseline'><span style='font-size:9.5pt;font-family:"Helvetica","sans-serif";color:#373940'>SACRAMENTO — The Senate Health committee will consider legislation that would streamline access to experimental treatments for terminally ill patients.<span class=apple-converted-space> </span><a href="http://leginfo.legislature.ca.gov/faces/billHistoryClient.xhtml" target="_blank"><span style='font-size:12.0pt;color:#0073AD;border:none windowtext 1.0pt;padding:0in'>AB 159</span></a>, also known as the “Right to Try Act”, </span><span style='font-size:9.5pt;font-family:"Helvetica","sans-serif";color:#1F497D'>…</span><span style='font-size:9.5pt;font-family:"Helvetica","sans-serif";color:#373940'>patient has a serious or immediate life-threatening conditio</span><span style='font-size:9.5pt;font-family:"Helvetica","sans-serif";color:#1F497D'>n</span><span style='font-size:9.5pt;font-family:"Helvetica","sans-serif";color:#373940'> …<o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span style='color:#1F497D'>>…</span>Cool! <span style='color:#1F497D'>…</span> We should try something, anything. Hell Mary, we know what happens if we do nothing…<span style='color:#1F497D'> </span>spike<span style='color:#1F497D'><o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Imagine a public database with a description of the (anonymized) patient’s condition, as many metrics as we can get, a list of therapies being used and the results. Imagine another public database where anyone can donate an idea for treating one of the Hell Mary patients, perhaps along with a hypothetical line of reasoning for why that should be tried.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Example, imagine someone suggested taro root for a terminal prostate cancer patient, reasoning that the yang overpowered the yin and taro is simultaneously a yinizing agent and yangosuppressant according to health guru Dr. Nick Riviera. Disregard. <o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>But if it says try the extract from the wild palmetto berry because the local indigenous population were eating the berries for that purpose back when the Europeans arrived and shot them for being too slow to confess their sins and accept Christianity, well hmmmm, that might be worth a Hell Mary play, especially after the medics have given up.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>The follow-up will be to document what was used and how the patient did after that. Then we figure out some kind of numerical code for each treatment used and in what quantities, along with a numerically coded outcome metric. We need to create a numerical system for everything, for which we need the medics’ help (I have no idea how to create metrics for the outcome of a drug or therapy (a 1-0 scale for patient lived or died won’t work (not enough resolution.))) <o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Then we do a distributed background computing project where we do a Fourier calculus of variation style analysis, looking for any pattern anywhere, such as the taro root eaters perished in 68 days whereas the palmetto berry devourers lasted 97 days after correcting for other factors. <o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>We distribute the computing task over a jillion computers because the calculation task is enormous in multivariate calculus of variation. It chooses one factor to compare, the taro vs palmetto for instance, and finds all the ways to compare all other known factors by trial and error. This is the kind of analysis that cannot be done without enormous computing capacity, so it is a new-ish capability we have today, enabled by the internet and all these high-powered computers sitting around doing nothing 99% of the time even while we are using them.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>spike<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'> <o:p></o:p></span></p></div></body></html>